Table 1. Two-Sample Mendelian Randomization Examining the Bidirectional Relationship Between Genetic Predictors of Psoriasis and Coronary Artery Disease (CAD)/Strokea.
| Exposure | Outcome | Unadjusted model OR (95% CI) | Unadjusted model P value | CAD-adjusted OR (95% CI) | CAD-adjusted P value | Stroke-adjusted OR (95% CI) | Stroke-adjusted P value | Confounder-adjusted model OR (95% CI)b | Confounder-adjusted model P valueb |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis (109 variants) | CAD | 1.01 (0.99-1.03) | .12 | NA | NA | NA | NA | NA | NA |
| Psoriasis (109 variants) | Stroke | 1.00 (0.98-1.02) | .77 | NA | NA | NA | NA | NA | NA |
| CAD (234 variants) | Psoriasis | 1.07 (1.04-1.10)c | .003c | 1.04 (0.98-1.09) | .21 | NA | NA | 1.06 (1.01-1.11)c | .02c |
| Stroke (47 variants) | Psoriasis | 1.22 (1.05-1.41)c | .01c | NA | NA | 1.14 (0.97-1.35) | .12 | 1.17 (1.05-1.29)c | .02c |
Abbreviations: NA, not applicable; OR, odds ratio.
a
Adjustments for stroke/CAD effects and key confounders assessed using multivariable MR.
b
Key confounders included collectively in a multivariable mendelian randomization model: body mass index, waist to hip ratio, smoking, systolic blood pressure, diastolic blood pressure, hemoglobin A1c, total cholesterol, triglycerides, and low-density lipoprotein cholesterol.
c
Statistically significant (P < .05) results.